ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0582 • ACR Convergence 2023

    Evaluation of Anifrolumab Treatment Responses by the Short Form 36 Health Survey Version 2 in SLE: A Post Hoc Analysis of the Placebo-Controlled Phase 3 Long-Term Extension Trial

    Vibeke Strand1, Kenneth Kalunian2, Barnabas Desta3, Caroline Seo4, Gabriel Abreu5, Raj Tummala3, Catharina Lindholm5 and Hussein Al-Mossawi6, 1Stanford University, Palo Alto, CA, 2University of California San Diego, La Jolla, CA, 3BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 4BioPharmaceuticals Medical Evidence, AstraZeneca, Gaithersburg, MD, 5BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 6BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

    Background/Purpose: SLE is a chronic disease that progressively reduces patients’ health-related quality of life.1 In a post hoc analysis of the TULIP trials, patients with…
  • Abstract Number: 0585 • ACR Convergence 2023

    The Impact of Impaired Vagus Nerve Activity and Transcutaneous Vagus Nerve Stimulation (tVNS) on Arterial Stiffness in Systemic Lupus Erythematosus (SLE)

    Tobias Schmidt1, Christina Brock2, Jesper Fleischer3, Søren Jacobsen1 and Amanda Hempel Zinglersen1, 1Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 2Department of Gastroenterology and Hepatology, Aalborg University Hospital and Clinical Institute, Aalborg, Denmark, 3Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease with an increased risk of atherosclerosis. The development of atherosclerosis in SLE cannot be…
  • Abstract Number: 0528 • ACR Convergence 2023

    Risk of Cardiovascular Disease Associated with Long-term Use of NSAIDs in Ankylosing Spondylitis

    Seong-Kyu kim1, Ji-Won kim1, Jun Sik Yoon2, bo young Kim3, Hwajeong Lee1, Sung-Hoon Park1 and Jung-Yoon Choe1, 1Daegu Catholic University School of Medicine, Daegu, South Korea, 2Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea, 3Daegu Catholic University Medical Center, Daegu, South Korea

    Background/Purpose: Ankylosing spondylitis (AS) is associated with increased cardiovascular disease, but there are limited data as to whether prolonged treatment with non-steroidal anti-inflammatory drugs (NSAIDs)…
  • Abstract Number: 0594 • ACR Convergence 2023

    Baseline Innate Immunity Transcriptional Signatures Act as Predictors of Response to Immunosuppressive and Biologic Treatments in Systemic Lupus Erythematosus While Disturbances Linked to p53-signaling Define “Resistant” Disease

    Panagiotis garantziotis1, Georgia-Savina Moysidou2, stavros doumas3, Dionysis nikolopoulos2, Sofia Flouda4, Noemin kapsala2, Anastasia Filia2, George Sentis2, Antonis Fanouriakis2, George Bertsias5 and Boumpas Dimitrios6, 1Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 2School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, 3Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, 4Unit of Attikon University Hospital, Athens, Greece, 5Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece, 6National and Kapodistrian University of Athens, Athens, Greece

    Background/Purpose: Despite recent advances, the current state of SLE therapeutics remains largely empirical with existing immunosuppressive treatments failing to induce remission in over 40% of…
  • Abstract Number: 0563 • ACR Convergence 2023

    Urinary Neutrophil Gelatinase-associated Lipocalin (NGAL) as a Mediator of the Association Between Particulate Matter Exposure and Disease Activity in Systemic Lupus Erythematosus

    Ji-Hyoun Kang1, Hyemin Jeong2, Sung-Eun Choi2, Dong-Jin Park2, Han Joo Baek3, Hyo-Jin Choi4, Jae Hyun Jung5 and Shin-Seok Lee2, 1Chonnam National University Hospital, Gwangju, South Korea, 2Chonnam National University Medical School & Hospital, Gwangju, South Korea, 3Gil Medical Center, Gachon University College of Medicine, Inchon, South Korea, 4Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea, 5Korea University Ansan Hospital, Ansan-si, South Korea

    Background/Purpose: Neutrophil gelatinase-associated lipocalin (NGAL) is an acute-phase glycoprotein increased by inflammatory stimuli, oxidative stress, and tissue injury. Although NGAL is associated with global and…
  • Abstract Number: 0597 • ACR Convergence 2023

    Efficacy of Anifrolumab in Systemic Lupus Erythematosus by Overall and Organ-Specific SLEDAI-2K Improvements: Results from the Randomized, Placebo-Controlled Phase 3 Long-Term Extension Study

    Richard A. Furie1, Kenneth Kalunian2, Eric Morand3, Ian Bruce4, Susan Manzi5, Yoshiya Tanaka6, Kevin Withrop7, Ihor Hupka8, Micki Hultquist9, Raj Tummala9, Gabriel Abreu10, Catharina Lindholm10 and Hussein Al-Mossawi11, 1Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 2University of California San Diego, La Jolla, CA, 3Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, 4University of Manchester, Manchester, United Kingdom, 5Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, 6University of Occupational and Environmental Health, Kitakyushu, Japan, 7Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, 8BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland, 9BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 10BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 11BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

    Background/Purpose: SLE is a systemic autoimmune disease requiring long-term treatment. In this placebo-controlled phase 3 TULIP long-term extension (LTE) study,1 the impact of anifrolumab in…
  • Abstract Number: 0492 • ACR Convergence 2023

    Axial Spondyloarthritis in Patients with Late-Onset Chronic Low Back Pain (Older Than 45 Years). Axial Spa or Psoriatic Disease with Axial Involvement?

    rodrigo garcía salinas1, Gisel Reyes2, Rosario Jaldín Céspedes2, Felica Almada2 and Sebastián Juan Magri3, 1Arthritis and Spondyloarthritis Unit, Hospital Italiano de La Plata, National University of La Plata, La Plata, Argentina, 2Hospital Italiano de La Plata, La Plata, Argentina, 3Hospital Italiano La Plata, Melchor Romero, Argentina

    Background/Purpose: It is known that patients diagnosed with axSpA do not subsequently meet the classification criteria. The Objectives are: To estimate the diagnostic prevalence of…
  • Abstract Number: 0605 • ACR Convergence 2023

    Determining the ECG Cut-off Point in Systemic Lupus Erythematosus Patients Undergoing Hydroxychloroquine Therapy

    Carmen Lasa1, Alba Herrero-Morant2, Jon Zubiaur3, Adrián Margarida4, Raquel Pérez3 and Ricardo Blanco5, 1Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, 2Hospital Universitario Marqués de Valdecilla, Ontinyent, Spain, 3Hospital Universitario Marqués de Valdecilla, Santander, Spain, 4Hospital Universitario Marqués de Valdecilla., Santander, Spain, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Hydroxychloroquine (HCQ) is a widely used drug in Systemic Lupus Erythematosus (SLE) that can cause cardiac alterations such as arrhythmic events in the short-term…
  • Abstract Number: 0604 • ACR Convergence 2023

    Is Belimumab Dose Optimization Possible in Patients with Systemic Lupus Erythematosus?: Analysis of This Therapeutic Strategy in a Large Multicenter Cohort of Patients from Spanish Rheumatology Departments

    Irene Altabas Gonzalez1, Jose-Maria Pego-Reigosa2, CORAL Mourino Rodriguez3, Norman Jiménez4, Andrea Hernández-Martín5, Judit Font6, Ivette Casafont-Sole7, Jose Andres Roman Ivorra8, Marta De la Rubia Navarro9, Maria Galindo10, TAREK CARLOS SALMAN MONTE11, Javier Narvaez12, Paola Vidal-Montal13, Maria J. García-Villanueva14, Sandra Garrote Corral14, María Ángeles Blázquez Cañamero15, carlos Marras Fernández-Cid16, María Piqueras García17, JULIA MARTINEZ BARRIO18, Marina Sánchez-Lucas19, Josefina Cortés Hernández20, Eleonora Penzo21, Jaime Calvo Alén22, Juan Ramón de Dios Jiménez de Aberásturi23, Belén Álvarez Rodríguez24, Margarida Rocha25, Eva Tomero Muriel26, Raúl Menor-Almagro27, Myriam Gandía Martínez28, Jose A Gomez-Puerta29, Beatriz Frade30, Consuelo Ramos-Giráldez31, Carmen Trapero Pérez32, MARIA ELVIRA DIEZ ALVAREZ33, Clara Moriano Morales33, Alejandro Muñoz34 and Iñigo Rúa-Figueroa35, 1Complejo Hospitalario Universitario de Vigo, IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, 2Rheumatology, Hospital do Meixoeiro, Vigo, Spain, 3Complejo Hospitalario Universitario de Vigo. IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, 4IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, 5Hospital Universitario de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, Spain, 6Hospital Universitario Germans Trias i Pujol, Badalona, Spain, 7Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 8Hospital Universitari i Politècnic la Fe, Valencia, Spain, 9Hospital Universitario y Politécnico de la Fe, Valencia, Spain, 10Hospital Universitario 12 de Octubre, Madrid, Spain, 11Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, 12Hospital Universitario de Bellvitge, Barcelona, Spain, 13Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain, 14Hospital Ramón y Cajal, Madrid, Spain, 15Rheumatology Department Hospital Ramon y Cajal, Madrid, Spain, 16Rheumatology, Hospital Virgen Arrixaca, Murcia, Spain, 17Hospital Virgen de la Arrixaca de Murcia, Murcia, Spain, 18Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, 19Hospital General Universitario Gregorio Marañón, Madrid, Spain, 20Lupus Unit, Rheumatology Department, Vall d’Hebron Hospitals, Barcelona, Spain, 21Hospital Universitario Valle d´ Hebrón, Barcelona, Spain, 22Hospital Universitario Araba, Vitoria, Spain, 23Hospital Universitario Araba, Álava, Spain, 24Hospital de Araba, Vitoria, Spain, 25Osakidetza, Bilbo, Spain, 26Rheumatology, Hospital La Princesa, Madrid, Spain, 27Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, 28Hospital de Jerez, Jerez, Spain, 29Department of Rheumatology, Hospital Clinic of Barcelona, Barcelona, Spain, 30Hospital Clinic, Barcelona, Spain, 31Rheumatology Department Hospital Universitario Virgen de Valme, Sevilla, Spain, 32Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain, 33Rheumatology, Hospital Universitario de León, León, Spain, 34Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, 35Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain

    Background/Purpose: Belimumab (BLM) is an IgG-1l anti-BAFF monoclonal antibody effective in patients with systemic lupus erythematosus (SLE), being used increasingly. However, there are no published…
  • Abstract Number: 0504 • ACR Convergence 2023

    Burden of Disease of Psoriatic Arthritis in Latin America: A Systemic Review of Literature

    Wilson Bautista-Molano1, Linda Ibata2, Susan Martinez2 and Andrea Chacon2, 1University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia, 2InValue Health Solutions, Bogotá, Colombia

    Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory pathology that generates a substantial and progressive deterioration of functionality and quality of life. It is associated…
  • Abstract Number: 0569 • ACR Convergence 2023

    Serum S100A8 and S100A9 Are Useful Biomarker Indicated IFN Associated Organ Involvements in Systemic Lupus Erythematosus

    Risa Wakiya1, Hiromi Shimada1, Shusaku Nakashima1, Taichi Miyagi2, Yusuke Ushio3, Koichi Sugihara4, Mao Mizusaki1, Rina Mino5, Kanako Chujo6, Ryoko Kagawa3, Hayamasa Yamaguchi3, Tomohiro Kameda1 and Hiroaki Dobashi1, 1Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, 2Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, 3Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, 4Kagawa University, Miki-cho, Kita-gun, Japan, 5Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, 6Kagawa University, Miki, Kita District, Kagawa, Japan

    Background/Purpose: S100, a damage-related molecular pattern factor, was reported to be a biomarker associated with disease activity in SLE. Additional hydroxychloroquine, which could regulate IFN…
  • Abstract Number: 0626 • ACR Convergence 2023

    Clinical Features of Anti-hUBF Antibodies-positive Patients: A Single-center Retrospective Study

    Natsumi Fushida, Motoki Horii, Kie Mizumaki, Natsuki Numata, Yasuhito Hamaguchi and Takashi Matsushita, Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa Ishikawa, Japan

    Background/Purpose: Anti-human upstream-binding factor (hUBF) antibodies (Abs) have been reported predominantly in patients with connective tissue diseases (CTDs) but have also been reported in non-CTDs…
  • Abstract Number: 0577 • ACR Convergence 2023

    Analysis of Intracytoplasmic Toll – Like Receptors (TLRs) and MyD88 Expression in B Cell Subsets in Patients with Lupus Nephritis

    Michelle Patricia Loeza-Uribe1, Michelle Nicolle Espinoza-Carranza1, Yatzil Reyna-Juárez1, Beatriz Alcalá-Carmona1, Nancy Raquel Mejía-Domínguez2, Guillermo Juárez-Vega2, José Luis Maravillas-Montero2, Karina Santana-de Anda1, José Jiram Torres-Ruiz1 and Diana Gómez-Martín1, 1Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Mexico

    Background/Purpose: Intrinsic signaling of intracytoplasmic TLRs (7 and 9) and MyD88 in B cells (BC) plays an important role in the development and pathogenesis of…
  • Abstract Number: 0513 • ACR Convergence 2023

    Impact of Pregnancy on Sacroiliac Imaging in Women with Axial Spondyloarthritis: Results of the Analysis of the DESIR Cohort

    Elodie Portier1, Maxime Dougados2, Adeline Ruyssen-Witrand3 and Anna Molto4, 1Hôpital Cochin, Paris, France, 2Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France, 3Toulouse University Hospital, Toulouse, France, 4HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France

    Background/Purpose: Axial spondyloarthritis (axSpA) is typically characterized by imaging (radiographs or MRI) abnormalities of the sacroiliac joints (SIJ). Also, inflammatory lesions of the SIJ have…
  • Abstract Number: 0637 • ACR Convergence 2023

    Comparison of Four Risk Stratification Models for Prediction of Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in the EUSTAR Cohort

    Hilde Jenssen Bjørkekjær1, Cosimo Bruni2, Cathrine Brunborg3, Patricia Carreira4, Paolo Airò5, Carmen Pilar Simeon-Aznar6, Marie-Elise Truchetet7, Alessandro Giollo8, Alexandra Balbir-Gurman9, Mickael Martin10, Christopher Denton11, Armando Gabrielli12, Havard Fretheim13, Imon Barua13, Helle Bitter14, Oyvind Midtvedt13, Torhild Garen15, Kaspar Broch16, Arne Andreassen17, Yoshiya Tanaka18, Gabriela Riemekasten19, Ulf Müller-Ladner20, marco Matucci Cerinic21, Ivan Castellvi22, Elise Siegert23, Eric Hachulla24, Oliver Distler2 and Anna-Maria Hoffmann-Vold13, 1Department of Rheumatology, Hospital of Southern Norway, Kristiansand & University of Oslo, Institute of Clinical Medicine, Oslo, Norway, 2Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 3Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, 4Hospital Universitario 12 de Octubre, Madrid, Spain, 5Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, 6Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitario Vall d'Hebronh, Barcelona, Spain, 7Bordeaux University Hospital, Bordeaux, France, 8University of Verona, Rheumatology Section, Department of Medicine, Verona, Italy, Verona, Italy, 9Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, 10Department of Internal Medicine, INSERM U1313, Poitiers University, Poitiers University Hospital, Poitiers, France, 11University College London, London, United Kingdom, 12Ospedali Riuniti Marche, Ancona, Italy, 13Oslo University Hospital, Oslo, Norway, 14Sorlandet sykehus, Kristiansand, Norway, 15Dept of Rheumatology, University Hospital Oslo, Oslo, Norway, 16Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, KG Jebsen center, Institute for Experimental Medical Research, University of Oslo, Oslo, Norway, 17Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, 18University of Occupational and Environmental Health, Kitakyushu, Japan, 19University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, 20Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, 21Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, 22Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, 23Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, 24University of Lille, Lille, France

    Background/Purpose: The 2022 ESC/ERS Guidelines recommend comprehensive risk stratification at diagnosis of pulmonary arterial hypertension (PAH) to guide optimized management.1Several risk stratification tools have been…
  • « Previous Page
  • 1
  • …
  • 305
  • 306
  • 307
  • 308
  • 309
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology